Propanc Biopharma (NASDAQ:PPCB) Trading Down 5.5% – Time to Sell?

Propanc Biopharma Inc (NASDAQ:PPCB)’s stock price fell 5.5% during trading on Monday . The company traded as low as $1.31 and last traded at $1.37. 28,973 shares were traded during trading, a decline of 55% from the average session volume of 64,605 shares. The stock had previously closed at $1.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Propanc Biopharma Stock Down 5.5%

The business’s fifty day moving average price is $2.32 and its 200 day moving average price is $7.64. The firm has a market capitalization of $3.12 million, a PE ratio of -0.06 and a beta of 3.48.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC purchased a new position in shares of Propanc Biopharma Inc (NASDAQ:PPCB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma as of its most recent SEC filing.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.